Market News AIOpen the app

Fresenius Medical Care is changing its plans in China to focus on specific products.

MarketRead the original at Benzinga
Neutral

Fresenius is focusing on advanced dialysis products in China but will stop selling its 4008A system and leave peritoneal dialysis there. It expects a one-time charge of €110 million, but says China segment revenue forecasts will not change.

FMS · Fresenius Medical Care AG

AI read · Neutral

The AI's read

The shift puts more attention on advanced in-center treatment, where Fresenius says local demand is growing. But the company expects no change to China revenue forecasts and must absorb a one-time charge as it exits two product areas. That leaves no clear change to its business outlook.

Get alerts for FMS

Follow Fresenius Medical Care AG (FMS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for FMS
Free on the App Store and Google Play, or on the web.